Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer

Clinical Nuclear Medicine

Volumn 38, Issue 10, 2013, Pages 778-783

  Moon, Soo Young ^a   Joo, Kwang Ro ^a   So, Ye Ri ^a   Lim, Jun Uk ^a   Cha, Jae Myung ^a   Shin, Hyun Phil ^a   Yang, You Jung ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Chemotherapy; Pancreatic cancer; PET CT; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METASTASIS; PANCREAS CANCER; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; SOLID TUMOR; TREATMENT RESPONSE;

AGED; BLOOD GLUCOSE; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84897711681     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31829f8c90     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Shin HR, Jung KW,Won YJ, et al. 139 KCCR-affiliated hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat. 2004;36:103-114.
3. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180.
4. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14:118-127.
5. Hawes RH, Xiong Q,Waxman I, et al. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000;95:17-31.
6. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
7. Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13.
8. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin N Am. 2001;39:883-917.
9. Higashi T, Saga T,NakamotoY, et al. Diagnosis of pancreatic cancer using fluorine- 18 fluorodeoxyglucose positron emission tomography(FDG PET)Vusefulness and limitations in "clinical reality". Ann Nucl Med. 2003;17:261-279.
10. Zimny M, Fass J, Bares R, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol. 2000;35:883-888.
11. Nakata B, Nishimura S, Ishikawa T, et al. Prognostic predictive value of 18Ffluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol. 2001;19:53-58.
12. Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7:953-959.
13. Schellenberg D, Quon A, Minn AY, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420-1425.
14. Kloppel G, Solcia E, Longnecker DS, et al. Histological Typing of Tumours of the Exocrine Pancreas (2nd edn.) WHO International Histological Classification of Tumours. Berlin: Springer Verlag; 1996.
15. Sobin LH, Wittekind WC, eds. TNM Classification of Malignant Tumours (UICC). 6th ed. New York: Wiley-Liss; 2002:93-96.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
17. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
18. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst. 2004;96:1805-1806.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
20. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24SY42S.
21. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419.
22. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39: 1727-1735.
23. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101.
24. Lee SM, Kim TS, Lee JW, et al. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med. 2011;36:331-336.
25. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
26. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancerVa PET study. J Nucl Med. 1993;34: 1-6.
27. Diederichs CG, Staib L, Glatting G, et al. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033.
28. Na II, Byun BH, Kang HJ, et al. 18F-Fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res. 2008;14:2036-2041.
29. Döbert N, Kovács AF, Menzel C, et al. The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. Q J Nucl Med Mol Imaging. 2005;49:253-257.
30. max in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol. 2009;4:875-879.